Cohen Klingenstein’s Takeda Pharmaceutical TAK Stock Holding History

Cohen Klingenstein’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-22,771	Closed	-$295K	–	225
2022 Q3	$295K	Hold	22,771	–	–	0.02%	210
2022 Q2	$320K	Hold	22,771	–	–	0.02%	210
2022 Q1	$326K	Hold	22,771	–	–	0.01%	212
2021 Q4	$310K	Sell	22,771 -1,988	-8%	-$27.9K	0.01%	213
2021 Q3	$406K	Sell	24,759 -3,251	-12%	-$54.6K	0.02%	223
2021 Q2	$471K	Hold	28,010	–	–	0.02%	215
2021 Q1	$511K	Hold	28,010	–	–	0.02%	212
2020 Q4	$510K	Hold	28,010	–	–	0.03%	206
2020 Q3	$500K	Hold	28,010	–	–	0.03%	199
2020 Q2	$502K	Hold	28,010	–	–	0.03%	197
2020 Q1	$425K	Hold	28,010	–	–	0.03%	198
2019 Q4	$553K	Hold	28,010	–	–	0.03%	201
2019 Q3	$482K	Hold	28,010	–	–	0.03%	206
2019 Q2	$496K	Hold	28,010	–	–	0.04%	176
2019 Q1	$571K	Buy	+28,010	New	+$564K	0.04%	143

Other funds holding TAK

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cohen Klingenstein's TAK Position: Q4 2022 in Review

Cohen Klingenstein sold out of Takeda Pharmaceutical (TAK) in Q4 2022, closing a stake of 22,771 shares — an estimated $295K sold.

Cohen Klingenstein first reported a position in TAK in Q1 2019 and held it in 15 quarters. The position peaked at $571K in Q1 2019. 281 funds tracked by Wall St. Rank hold TAK as of Q4 2022.

Cohen Klingenstein reported no remaining Takeda Pharmaceutical position as of Q4 2022 after selling out during the quarter.
Cohen Klingenstein sold 22,771 Takeda Pharmaceutical shares in Q4 2022, an estimated $295K.
Cohen Klingenstein first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 15 quarters.
Cohen Klingenstein's Takeda Pharmaceutical position peaked at $571K in Q1 2019.
281 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2022.

Based on Cohen Klingenstein's 13F filing for Q4 2022, filed 13 Jan 2023.